Assess whether biosimilarity is analytically justified (f27caf)

Situation

A labeling team facing a boxed-warning debate cannot treat an inspector asking for batch records you cannot produce this week as color commentary on biosimilar analytical similarity report. Pharmacovigilance medical reviewer must close biosimilarity is analytically justified from that extract under Pharma & Life Sciences / Pharmacovigilance.

Decision

Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• An inspector asking for batch records you cannot produce this week is noise around an already-controlled Pharmacovigilance process in a labeling team facing a boxed-warning debate, given biosimilar analytical similarity report.
• An inspector asking for batch records you cannot produce this week is the event in biosimilar analytical similarity report that forces Proceed under protocol for pharmacovigilance medical reviewer under Pharma & Life Sciences.
• Biosimilar analytical similarity report shows a one-file miss after an inspector asking for batch records you cannot produce this week, not a Pharmacovigilance program failure.
• Biosimilar analytical similarity report cannot decide biosimilarity is analytically justified yet after an inspector asking for batch records you cannot produce this week; hold is the only Pharma & Life Sciences close a labeling team facing a boxed-warning debate can defend.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after an inspector asking for batch records you cannot produce this week.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• For this Pharma & Life Sciences Pharmacovigilance file, read biosimilar analytical similarity report against an inspector asking for batch records you cannot produce this week and write the one fact that would move biosimilarity is analytically justified for pharmacovigilance medical reviewer.

Recommendation